U.S. Pharmacist Weekly News

July 17, 2024

ADEs Most Common With Cardiovascular Medications in Outpatients

Limited information is available on adverse drug events (ADEs) in outpatients, even though considerable data exist for hospitalized patients. A study led by researchers from Brigham and Women’s Hospital and Harvard Medical School in Boston and published in BMJ Quality & Safety sought to remedy that, finding approximately 5% of more than 13,000 outpatients experienced an ADE. Read more.

Addressing Modifiable Risk Factors Could Avoid Half of U.S. Cancer Deaths

A surprising study result suggests that one-half of all U.S. cancer deaths could be prevented by modifiable factors, many involving vaccinations and medications, such as smoking cessation products. The researchers reported that cigarette smoking was the leading risk factor contributing to cancer cases and deaths overall, followed by excess body weight and alcohol consumption. Read more.

Which Anticoagulant for Atrial Fibrillation Patients Is Best?

Patients with comorbid atrial fibrillation and liver cirrhosis are notoriously hard to treat with anticoagulants because of impaired coagulation balance. A new study published in the Annals of Internal Medicine evaluated the safety and effectiveness of three common medications and found that apixaban was less likely than rivaroxaban and warfarin to be linked to major hemorrhage events. Read more.

Applying and Removing the FreeStyle Libre Sensor

The FreeStyle Libre 3 system has been cleared by the FDA and is indicated for use in people with diabetes aged 4 years and older. Learn more about the FreeStyle Libre 3 system and how it can be an effective tool for glucose monitoring in diabetes management.